


**HIRAN ORGOCHEM LIMITED**

Registered Off: Unit 908,9th Floor, IJMIMA - Immitation Jewellery Market CSL, Raheja Metroplex, Link Road,  
Malad (West) Mumbai-400064

CIN: L51900MH1983PLC029596


E-mail: anu@hiranorgochem.com Phone: 022-40144126/7 ; Website: www.hiranorgochem.com

STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2016					
Rs. in Lacs					
Sr. No.	Particulars	Quarter ended 30.06.2016 (Unaudited)	Quarter ended 31.03.2016 (Audited)	Quarter ended 30.06.2015 (Unaudited)	Year ended 31.03.2016 (Audited)
1	(a) Net Sales /Income from Operations	-	-	-	-
	(b) Other Operating Income	-	-	-	-
	<b>Total Income from operation (a+b)</b>	-	-	-	-
2	<b>Expenditure</b>				
	a) (Increase)/Decrease in stock in trade	-	-	-	-
	b) Purchase of Shares traded in	-	-	-	-
	c) Employees cost	2.29	3.27	4.04	15.66
	d) Depreciation	1.31	1.30	-	5.25
	e) Other Expenditure	3.34	8.64	(4.13)	(26.44)
	<b>Total</b>	<b>6.94</b>	<b>13.21</b>	<b>(0.09)</b>	<b>(5.53)</b>
3	<b>Profit from Operations before Other Income, Interest &amp; Exceptional Items &amp; Tax (1-2)</b>	<b>(6.94)</b>	<b>(13.21)</b>	<b>0.09</b>	<b>5.53</b>
4	Other Income	-	92.86	-	92.86
5	<b>Profit before Interest &amp; Exceptional items &amp; Tax (3+4)</b>	<b>(6.94)</b>	<b>79.65</b>	<b>0.09</b>	<b>98.39</b>
6	Finance Cost	-	6.30	0.07	6.38
7	<b>Profit after interest but before Exceptional items (5-6)</b>	<b>(6.94)</b>	<b>73.35</b>	<b>0.02</b>	<b>92.01</b>
8	Exceptional items	-	-	-	-
9	<b>Profit (Loss) from Ordinary Activities before Tax (7+8)</b>	<b>(6.94)</b>	<b>73.35</b>	<b>0.02</b>	<b>92.01</b>
10	Tax Expenses	-	-	-	-
11	<b>Net Profit (Loss) from Ordinary Activities after Tax (9-10)</b>	<b>(6.94)</b>	<b>73.35</b>	<b>0.02</b>	<b>92.01</b>
	Add/(Less) Tax Adjustments for earlier year	-	-	-	-
12	Extraordinary items (net of tax expenses)	-	-	-	-
13	<b>Net Profit (Loss) for the period (11-12)</b>	<b>(6.94)</b>	<b>73.35</b>	<b>0.02</b>	<b>92.01</b>
14	Share of Profit / (Loss) of Associates	-	-	-	-
15	<b>Net Profit / (Loss) after Taxes, Minority Interest and Share of Profit / (Loss) of Associates (13-14)</b>	<b>(6.94)</b>	<b>73.35</b>	<b>0.02</b>	<b>92.01</b>
16	Paid-up Equity Share Capital (Face Value Rs. 10/- each)	9,865.69	9,865.69	9,865.69	9,865.69
17	Reserves Excluding Revaluation Reserves	-	-	-	-
18	Earnings Per Share (EPS)				
	a) Basic and diluted EPS before Extraordinary items for the period , for the year to date and for the previous year (not annualized)	(0.01)	0.07	0.00	0.09
	b) Basic and diluted EPS after Extraordinary items for the period, for the year to date and for the previous year (not annualized)	(0.01)	0.07	0.00	0.09



Notes :

- 1) Company's accounts with State Bank of India, State Bank of Patiala and SICOM Ltd have been classified as NPA by respective institution, hence the Company has not provided interest.
- 2) During the last year, all the fixed assets of the company are sold by Edelweiss Asset Management Company for 10.65 crores in an attempt to recover dues of State Bank of India. However, principle of going concern is not affected as per management.
- 3) Company is yet to transfer unclaimed dividends outstanding for a period of more than 7 years aggregating to Rs. 4.22 Lacs to Investors Protection Fund.
- 4) Foreign Exchange gain/loss for the outstanding debtors and creditors is not recognised as per with AS -11 issued by ICAI.
- 5) Company is in violation of Section 185 of Companies Act, 2013 relating to Loans & advances given to a company in which director is interested.
- 6) In view of substantial loss, provision for deferred tax has not been considered in conformity with AS -22 issued by ICAI.
- 7) Company during the year has accumulated losses more than its share capital. However, principle of going concern is not affected as per management.
- 8) Company is in violation of limits specified Section 186 of Companies Act, 2013 relating to limits of Loans & advances given by a company.
- 9) Company has provided interest free loan to a company, i.e. Actgen Pharma Private Limited, covered under section 189 of Companies Act, 2013. During the quarter Bank has taken possession of factory of Actgen Pharma Private Limited, an associate company, for which company has provided a corporate gurantee of 27 Crores. However, the gurantee has not been evoked till date.
- 10) Company is in process of compiling the details of pending assesments under various acts. Hence the impact of the same is not disclosed as contingent liability.
- 11) Company's financial assets constitute more than 50 per cent of the total assets and income from financial assets constitute more than 50 per cent of the gross income. However Company is not registered under section 45-IA of the Reserve bank of India as its net owned funds are not adequate for registration as NBFC.
- 12) Company Secretary in Whole-Time Employment has resigned in February, 2016 and hence there was no Company Secretary as on 30th June, 2016 as required u/s 203 of Companies Act, 2013. However, Company is in process of appointing a new Company secretary in whole-time employment.
- 13) The figures for the quarter ended June 30, 2016 as reported in these results are the balancing figures between audited figures in respect of the year ended June 30, 2016 and published year to date figures upto the end of third quarter of the relevant financial years.
- 14) Interest on short term Loans & Advances given are recognised at the end of the year and not on quarterly basis.
- 15) The above unaudited financial results for the quarter ended 30th June, 2016 have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meeting held on 11th August, 2016.



By order of the Board  
For Hiran Orgochem Limited

*Kanfilal Hiran*  
Director  
DIN: 00186885

Place : Mumbai  
Dated : 11/08/2016

**HIRAN ORGOCHEM LIMITED**

**Registered Off:** Unit 908,9th Floor, IJMIMA - Immitation Jewellery Market CSL, Raheja Metroplex, Link Road,  
Malad (West) Mumbai-400064  
**CIN:** L51900MH1983PLC029596

**E-mail:** anu@hiranorgochem.com **Phone:** 022-40144126/7 ; **Website:** www.hiranorgochem.com


**CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2016**

Rs. in Lacs					
Sr. No.	Particulars	Quarter ended 30.06.2016 (Unaudited)	Quarter ended 31.03.2016 (Audited)	Quarter ended 30.06.2015 (Unaudited)	Year ended 31.03.2016 (Audited)
1	(a) Net Sales / Income from Operations	-	-	-	-
	(b) Other Operating Income	-	-	-	-
	<b>Total Income from operation (a+b)</b>	-	-	-	-
2	<b>Expenditure</b>				
	a) (Increase)/Decrease in stock in trade	-	-	-	-
	b) Purchase of Shares traded in	-	-	-	-
	c) Employees cost	2.29	3.27	4.04	15.66
	d) Depreciation	1.31	1.30	-	5.25
	e) Other Expenditure	3.34	8.64	(4.13)	(26.44)
	<b>Total</b>	<b>6.94</b>	<b>13.21</b>	<b>(0.09)</b>	<b>(5.53)</b>
3	<b>Profit from Operations before Other Income, Interest &amp; Exceptional Items &amp; Tax (1-2)</b>	<b>(6.94)</b>	<b>(13.21)</b>	<b>0.09</b>	<b>5.53</b>
4	Other Income	-	92.86	-	92.86
5	<b>Profit before Interest &amp; Exceptional items &amp; Tax (3+4)</b>	<b>(6.94)</b>	<b>79.65</b>	<b>0.09</b>	<b>98.39</b>
6	Finance Cost	-	6.30	0.07	6.38
7	<b>Profit after interest but before Exceptional items (5-6)</b>	<b>(6.94)</b>	<b>73.35</b>	<b>0.02</b>	<b>92.01</b>
8	Exceptional items	-	-	-	-
9	<b>Profit (Loss) from Ordinary Activities before Tax (7+8)</b>	<b>(6.94)</b>	<b>73.35</b>	<b>0.02</b>	<b>92.01</b>
10	Tax Expenses	-	-	-	-
11	<b>Net Profit (Loss) from Ordinary Activities after Tax (9-10)</b>	<b>(6.94)</b>	<b>73.35</b>	<b>0.02</b>	<b>92.01</b>
	<b>Add/(Less) Tax Adjustments for earlier year</b>	-	-	-	-
12	Extraordinary items (net of tax expenses)	-	-	-	-
13	<b>Net Profit (Loss) for the period (11-12)</b>	<b>(6.94)</b>	<b>73.35</b>	<b>0.02</b>	<b>92.01</b>
14	Share of Profit / (Loss) of Associates	-	-	-	-
15	<b>Net Profit / (Loss) after Taxes, Minority Interest and Share of Profit / (Loss) of Associates (13-14)</b>	<b>(6.94)</b>	<b>73.35</b>	<b>0.02</b>	<b>92.01</b>
16	Paid-up Equity Share Capital (Face Value Rs. 10/- each)	9,865.69	9,865.69	9,865.69	9,865.69
17	Reserves Excluding Revaluation Reserves	-	-	-	-
18	<b>Earnings Per Share (EPS)</b>				
	a) Basic and diluted EPS before Extraordinary items for the period , for the year to date and for the previous year (not annualized)	(0.01)	0.07	0.00	0.09
	b) Basic and diluted EPS after Extraordinary items for the period, for the year to date and for the previous year (not annualized)	(0.01)	0.07	0.00	0.09



Notes :

- 1) Company's accounts with State Bank of India, State Bank of Patiala and SICOM Ltd have been classified as NPA by respective institution, hence the Company has not provided interest.
- 2) During the last year, all the fixed assets of the company are sold by Edelweiss Asset Management Company for 10.65 crores in an attempt to recover dues of State Bank of India. However, principle of going concern is not affected as per management.
- 3) Company is yet to transfer unclaimed dividends outstanding for a period of more than 7 years aggregating to Rs. 4.22 Lacs to Investors Protection Fund.
- 4) Foreign Exchange gain/loss for the outstanding debtors and creditors is not recognised as per with AS -11 issued by ICAI.
- 5) Company is in violation of Section 185 of Companies Act, 2013 relating to Loans & advances given to a company in which director is interested.
- 6) In view of substantial loss, provision for deferred tax has not been considered in conformity with AS -22 issued by ICAI.
- 7) Company during the year has accumulated losses more than its share capital. However, principle of going concern is not affected as per management.
- 8) Company is in violation of limits specified Section 186 of Companies Act, 2013 relating to limits of Loans & advances given by a company.
- 9) Company has provided interest free loan to a company, i.e. Actgen Pharma Private Limited, covered under section 189 of Companies Act, 2013. During the quarter Bank has taken possession of factory of Actgen Pharma Private Limited, an associate company, for which company has provided a corporate gurantee of 27 Crores. However, the gurantee has not been evoked till date.
- 10) Company is in process of compiling the details of pending assesments under various acts. Hence the impact of the same is not disclosed as contingent liability.
- 11) Company's financial assets constitute more than 50 per cent of the total assets and income from financial assets constitute more than 50 per cent of the gross income. However Company is not registered under section 45-IA of the Reserve bank of India as its net owned funds are not adequate for registration as NBFC.
- 12) Company Secretary in Whole-Time Employment has resigned in February, 2016 and hence there was no Company Secretary as on 30th June, 2016 as required u/s 203 of Companies Act, 2013. However, Company is in process of appointing a new Company secretary in whole-time employment.
- 13) The figures for the quarter ended June 30, 2016 as reported in these results are the balancing figures between audited figures in respect of the year ended June 30, 2016 and published year to date figures upto the end of third quarter of the relevant financial years.
- 14) Interest on short term Loans & Advances given are recognised at the end of the year and not on quarterly basis.
- 15) The above unaudited financial results for the quarter ended 30th June, 2016 have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meeting held on 11th August, 2016.



By order of the Board  
For Hiran Orgochem Limited

*Kanfilal Hiran*  
Director  
DIN: 00186885

Place : Mumbai  
Dated : 11/08/2016